Spotlight: The CMRR Ataxia Imaging Team

Location: University of Minnesota, MN, USA

Year Research Group Founded:  2008

What models and techniques do you use?

A photo of the CMRR Ataxia Imaging Team
A photo of the CMRR Ataxia Imaging Team in 2019. Front row, left to right – Diane Hutter, Christophe Lenglet (PI), Gulin Oz (PI), Katie Gundry, Jayashree Chandrasekaran Back row, left to right: Brian Hanna, James Joers, Pramod Pisharady, Kathryn France, Pierre-Gilles Henry (PI), Dinesh Deelchand, Young Woo Park, Isaac Adanyeguh (insert)

Research Group Focus

What shared research questions is your group investigating?

We use high field, multi-nuclear magnetic resonance imaging (MRI) and spectroscopy (MRS) to explore how diseases impact the central nervous system. These changes can be structural, functional, biochemical and metabolic alterations. For example, we apply advanced MRI and MRS methods in neurodegenerative diseases and diabetes.

We also lead efforts in research taking place at multiple different cities across the United States and the world. As you can imagine, studies spread out across such a big area require a lot of coordination and standardization. We design robust MRI and MRS methods to be used in clinical settings like these.

Another important question for our team is how early microstructural, chemical and functional changes can be detected in the brain and spinal cord by these advanced MR methods. We are interested in looking at these changes across all stages of disease.

Why does your group do this research?

The methods we use (MRI and MRS) can provide very helpful information to be used in clinical trials. These biomarkers we look at can provide quantitative information about how a disease is progressing or changing.

There is good evidence that subtle changes in the brain can be detected by these advanced MR technologies even before patients start having symptoms. If we better understand the earliest changes that are happening in the brain, this can in turn enable interventions at a very early stage. For example, we could treat people even before brain degeneration starts to take place.

Why did you form a research group connecting multiple labs?

We came together to form the CMRR Ataxia Imaging Team to benefit from our shared and complementary expertise, experience, and personnel. We can do more together than we could apart.

Are you recruiting human participants for research?

Yes, we are! We are looking for participants for multiple different studies. You can learn more about the research we are recruiting for at the following links: READISCA,  TRACK-FA, NAF Studies, and FARA Studies. More information is also available through the UMN Ataxia Center.

A photo of the CMRR Ataxia Imaging Team in 2016
A photo of the CMRR Ataxia Imaging Team in 2016, in front of the historic 4T scanner where the first functional MR images were obtained, in CMRR courtyard. Left to right – Christophe Lenglet (PI), Sarah Larson, Gulin Oz (PI), Dinesh Deelchand, Pierre-Gilles Henry (PI), James Joers, Diane Hutter

What Labs Make Up the CMRR Ataxia Imaging Team?

The Oz Lab

Principal Investigator:  Dr. Gulin Oz

Year Founded:  2006

Our focus is on MR spectroscopy, specifically neurochemistry and metabolism studies. We focus on spinocerebellar ataxias. Also, we have been leading MRS technology harmonization across different sites and vendors.

The Henry Lab

Principal Investigator: Dr. Pierre-Gilles Henry

Year Founded:  2006

We develop advanced methods for MR spectroscopy and motion correction. Then apply these new methods to the study of biochemistry and metabolism in the brain and spinal cord in various diseases. We have been working on ataxias since 2014.

Fun Fact about the Henry Lab: The French language can often be heard in discussions in our lab!

The Lenglet Lab

Principal Investigator:  Dr. Christophe Lenglet

Year Founded:  2011

We develop mathematical and computational strategies for human brain and spinal cord connectivity mapping. We do this using high field MRI. Our research aims at better understanding the central nervous system anatomical and functional connectivity. We are especially interested in looking at this in the context of neurological and neurodegenerative diseases.

Fun Fact

Members of our team have their roots in 7 countries (US, Turkey, France, India, Mauritius, South Korea, Ghana) and 4 continents (North America, Europe, Asia, Africa)

For More Information, check out the Center for Magnetic Resonance Research (CMRR) Website!


Written by Dr. Gulin Oz, Dr. Pierre-Gilles Henry, and Dr. Christophe Lenglet, Edited by Celeste Suart

Spotlight: The Zoghbi Lab

Baylor College of Medicine

Principal Investigator: Dr. Huda Zoghbi

Location: Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA

Year Founded:  1988

Logo: Texas Children's Hospital. Jan and Dan Duncan Neurological Research Institute

What models and techniques do you use?

Research Focus

What is your research about?

Our laboratory uses multiple methods to explore the underlying causes of different neurodegenerative and neurodevelopmental disorders. Some diseases we study affect children, like Rett Syndrome. Others affect adults, like spinocerebellar ataxia type 1 (SCA1), Alzheimer’s disease (AD) and Parkinson’s disease (PD). We also research how healthy brains grow and develop.

We first seek to understand the mechanism by which a mutant protein causes disease, allowing us to more thoughtfully and effectively develop therapeutic options for the diseases we study. Our work in SCA1 demonstrated that lowering levels of the disease-driving protein is beneficial in the course of disease, informing our approach to the study of other diseases of the brain.  

Why do you do this research?

We do this research to help the patients, families and caregivers affected by the diseases we study. Most of the disorders we study currently have no or very few treatment options available, and we hope to help in changing that.

Our lab began with Dr. Zoghbi seeing patients in the clinic who were diagnosed with Rett Syndrome and SCA1. Work with these patients allowed for the discovery of the genes causing these diseases. Today, we hope to aid in understanding how these diseases work and to develop therapies that can then be brought back to the clinic for patients. Furthermore, we hope our findings and the tools we’ve developed will aid in the study of other neurodevelopmental and neurodegenerative disorders.

A group picture of the Zoghbi Lab
Zoghbi Lab members at Hermann Park in Houston, TX in 2021. Bottom row L-R: Y. Sun, W. Wang, W. Lee, M. Zaghlula, H. Lee, S. Coffin, S. Wu, J. Butts, C. Adamski, H. Zoghbi (PI), Y. Shao, J. Johnson, J. Zhou, A. Tewari, H. Palikarana Tirumala, J. Lopez, Top row L-R: A. Anderson, E. Xhako, E. Villavicencio, Y. Li, S. Bajikar, M. Durham.

Fun Fact

On April 8, 1993, both Dr. Huda Zoghbi and Dr. Harry Orr identified the gene, ATXN1, which when mutated, is responsible for causing SCA1. You can read about this discovery here.

For More Information, check out the Zoghbi Lab website!


Written by Stephanie Coffin, Edited by Celeste Suart